<p>(<i>a</i>) Primary SC induce tumors in mice. (<i>b</i>) Tumor weight of the generated tumor xenografts from primary SC. (<i>c</i>) Xenograft derived from primary SC recapitulate the phenotype of the primary tumor after serial transplantation in mice. Magnification 10x. (<i>d</i>) Tumor growth in mice after injection of SC and their differentiated counterpart. Tumor incidence is indicated within the graph. Data are presented as mean ± SEM, *P<0.05.</p
<p><b><i>1A</i></b><i>,</i> representative FACS plots for MDSC in blood, BM, spleen and tumor of 3LL...
<p>5×10<sup>5</sup> CXCR6+ sorted cells were injected subcutaneously in five-week-old NOD-SCID mice ...
<p>(a). Mice (3–4 months old) were subcutaneously injected with 0.25×10<sup>6</sup> B16 melanoma cel...
<p>A, NOD/SCID mice were inoculated with 5,000 second-generation SP cells from a tumor formed with 2...
<p>The tumourigenicity was evaluated by the injection of SK cells into NOD/SCID/IL2rg mice, and seri...
<p>(A) Injection sites of nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. Hema...
<p>A, Tumor incidence from 3 experiments. Equal numbers of sex matched SCID mice were injected s.c. ...
<p>A, Table presentation of the tumorigenic potential of H460 SP and non-SP cells. Three parameters ...
<p>Xenografts-bearing mice were randomly assigned into four therapeutic groups (6–14 mice per group)...
<p>Tumor formation and growth were monitored in NOD/SCID mice orthotopically injected with hybrids o...
<p>Xenograft disease characteristics. Data is derived from 10 xenografted mice.</p
<p>Evaluation of the incidence of tumors in NOD/SCID mice implanted with different numbers of BCSCs ...
<p>A) Tumor volumes of xenografts generated by injection of spheres or adherent undifferentiated LMS...
<p>MOSEC tumors were established in C57BL/6 mice for 4 weeks. MSCs, <i>MSC1,</i> or <i>MSC2</i> (1×1...
<p>(A) 1×10<sup>6</sup> ES cells (MPI-II) or <i>in vitro</i> differentiated cells (day 14 of differe...
<p><b><i>1A</i></b><i>,</i> representative FACS plots for MDSC in blood, BM, spleen and tumor of 3LL...
<p>5×10<sup>5</sup> CXCR6+ sorted cells were injected subcutaneously in five-week-old NOD-SCID mice ...
<p>(a). Mice (3–4 months old) were subcutaneously injected with 0.25×10<sup>6</sup> B16 melanoma cel...
<p>A, NOD/SCID mice were inoculated with 5,000 second-generation SP cells from a tumor formed with 2...
<p>The tumourigenicity was evaluated by the injection of SK cells into NOD/SCID/IL2rg mice, and seri...
<p>(A) Injection sites of nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. Hema...
<p>A, Tumor incidence from 3 experiments. Equal numbers of sex matched SCID mice were injected s.c. ...
<p>A, Table presentation of the tumorigenic potential of H460 SP and non-SP cells. Three parameters ...
<p>Xenografts-bearing mice were randomly assigned into four therapeutic groups (6–14 mice per group)...
<p>Tumor formation and growth were monitored in NOD/SCID mice orthotopically injected with hybrids o...
<p>Xenograft disease characteristics. Data is derived from 10 xenografted mice.</p
<p>Evaluation of the incidence of tumors in NOD/SCID mice implanted with different numbers of BCSCs ...
<p>A) Tumor volumes of xenografts generated by injection of spheres or adherent undifferentiated LMS...
<p>MOSEC tumors were established in C57BL/6 mice for 4 weeks. MSCs, <i>MSC1,</i> or <i>MSC2</i> (1×1...
<p>(A) 1×10<sup>6</sup> ES cells (MPI-II) or <i>in vitro</i> differentiated cells (day 14 of differe...
<p><b><i>1A</i></b><i>,</i> representative FACS plots for MDSC in blood, BM, spleen and tumor of 3LL...
<p>5×10<sup>5</sup> CXCR6+ sorted cells were injected subcutaneously in five-week-old NOD-SCID mice ...
<p>(a). Mice (3–4 months old) were subcutaneously injected with 0.25×10<sup>6</sup> B16 melanoma cel...